Scinai Immunotherapeutics Reports Nine-Month 2026 Financial Results and CDMO Expansion

Scinai Immunotherapeutics reported nine-month 2026 revenue of $2.80 million, up 167% from $1.05 million a year earlier, reflecting the integration of operations acquired in February. The company recorded an operating loss of $6.56 million and a net loss of $0.39 million for the period. Its CDMO subsidiary expanded a U.S. customer agreement with approximately $5.1 million in committed base service fees; total committed customer orders reached about $8.32 million as of November 4, 2026, compared with $1.9 million at the end of 2025.